Literature DB >> 6231095

Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

R J North.   

Abstract

It was found that sublethal (550 rad) whole-body gamma-irradiation of mice bearing established immunogenic tumors enabled tumor-sensitized spleen cells infused intravenously 1 h later to cause complete tumor regression in all mice. In contrast, gamma-irradiation alone caused only a temporary halt in tumor growth, and immune cells gave practically no therapeutic effect at all. This result was obtained with the SA1 sarcoma, Meth A fibrosarcoma, P815 mastocytoma, and P388 lymphoma. Additional experiments with the Meth A fibrosarcoma revealed that the spleen cells from tumor-immune donors that caused tumor regression in gamma-irradiated recipients were T cells, as evidenced by their functional elimination by treatment with anti-Thy-1.2 antibody and complement. It was shown next that adoptive T-cell-mediated regression of tumors in gamma-irradiated recipients was inhibited by an intravenous infusion of spleen cells from donors with established tumors, but not by spleen cells from normal donors. The spleen cells that suppressed the expression of adoptive immunity were functionally eliminated by treatment with anti-Thy-1.2 antibody and complement. Moreover, they were destroyed by exposing the tumor-bearing donors to 500 rad of gamma-radiation 24 h before harvesting their spleen cells. The results are consistent with the interpretation that gamma-radiation facilitates the expression of adoptive T-cell-mediated immunity against established tumors by eliminating a population of tumor-induced suppressor T cells from the tumor-bearing recipient.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231095     DOI: 10.1007/bf00205425

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  In vivo splenic irradiation eradicates suppressor T-cells causing the regression and inhibition of established tumor.

Authors:  W E Enker; J L Jacobitz
Journal:  Int J Cancer       Date:  1980-06-15       Impact factor: 7.396

Review 2.  Passive immunotherapy of cancer in animals and man.

Authors:  S A Rosenberg; W D Terry
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

3.  In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.

Authors:  F Takei; J G Levy; D G Kilburn
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

4.  Characterization of suppressor cells in mice bearing syngeneic mastocytoma.

Authors:  F Takei; J G Levy; D G Kilburn
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

5.  Abrogation of the in vitro generation of the cytotoxic T-cell response to a murine tumor: the role of suppressor cells.

Authors:  P Frost; P Prete; R Kerbel
Journal:  Int J Cancer       Date:  1982-08-15       Impact factor: 7.396

6.  T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors:  E S Dye; R J North
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

7.  Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population.

Authors:  K E Hellström; I Hellström; J A Kant; J D Tamerius
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

8.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

9.  Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.

Authors:  C D Mills; R J North
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

10.  Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2.

Authors:  T J Eberlein; M Rosenstein; S A Rosenberg
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

View more
  29 in total

1.  Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

Authors:  Hilko Ardon; Stefaan Van Gool; Isabel Spencer Lopes; Wim Maes; Raf Sciot; Guido Wilms; Philippe Demaerel; Patricia Bijttebier; Laurence Claes; Jan Goffin; Frank Van Calenbergh; Steven De Vleeschouwer
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

Review 2.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

Authors:  Paul Andrew Antony; Nicholas P Restifo
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

3.  Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

Authors:  R J North; E S Dye
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

4.  Evaluation of in vivo and in vitro effectivity of immune defense against a spontaneously arising, nonlymphoid rat tumor. II. T cell response after induction of immunogenicity.

Authors:  M Zöller
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity.

Authors:  T P Archer; P Bretscher; B Ziola
Journal:  Clin Exp Metastasis       Date:  1990 Nov-Dec       Impact factor: 5.150

6.  The therapeutic significance of concomitant antitumor immunity. I. LY-1-2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Rat model of fractionated (2 Gy/day) 60 Gy irradiation of the liver: long-term effects.

Authors:  Margret Rave-Fränk; Ihtzaz Ahmed Malik; Hans Christiansen; Naila Naz; Sadaf Sultan; Ahmad Amanzada; Martina Blaschke; Silke Cameron; Shakil Ahmad; Clemens Friedrich Hess; Giuliano Ramadori; Federico Moriconi
Journal:  Radiat Environ Biophys       Date:  2013-04-18       Impact factor: 1.925

9.  Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice.

Authors:  Shuang Wei; Martin U Egenti; Seagal Teitz-Tennenbaum; Weiping Zou; Alfred E Chang
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

10.  Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.

Authors:  Jodi L Yorty; Satvir S Tevethia; Todd D Schell
Journal:  Cancer Immunol Immunother       Date:  2007-11-15       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.